Meeting
2011 ASCO Annual Meeting
Bendamustine and lenalidomide in relapsed/refractory lymphoid malignancies.
Authors
B. D. Cheson
Georgetown University Medical Center, Washington, DC
B. D. Cheson , C. S. Ujjani , S. M. Karim , T. Goswami , J. Crawford , E. A. Gehan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT00864942
Citation
J Clin Oncol 29: 2011 (suppl; abstr 8066)
Abstract #
8066
Poster Bd #
47F
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/ALLIANCE.
First Author: Grzegorz S. Nowakowski
Poster
2022 ASCO Annual Meeting
inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.
First Author: Laurie Helen Sehn
Poster
2021 ASCO Annual Meeting
Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
First Author: Catherine Thieblemont